Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
5.31
+0.21 (4.12%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Jupiter Neurosciences Revenue
Jupiter Neurosciences had revenue of $18.65K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $40.45K. In the year 2025, Jupiter Neurosciences had annual revenue of $21.80K.
Revenue (ttm)
$40.45K
Revenue Growth
n/a
P/S Ratio
76.01
Revenue / Employee
$8,090
Employees
5
Market Cap
3.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.80K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
JUNS News
- 4 days ago - Jupiter Neurosciences Inc trading halted, news pending - TheFly
- 5 days ago - Jupiter Neurosciences announces 1-for-75 reverse stock split - TheFly
- 5 days ago - Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 18 days ago - Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences - TheFly
- 20 days ago - Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal - TipRanks
- 20 days ago - PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences - TheFly
- 20 days ago - Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million - GlobeNewsWire
- 4 weeks ago - Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson - GlobeNewsWire